Evidence map›Paper›PMID 29768408›Full record

ArticlePLoS genetics2018

A homozygous KAT2B variant modulates the clinical phenotype of ADD3 deficiency in humans and flies.

Sara Gonçalves, Julie Patat, Maria Clara Guida, Noelle Lachaussée, Christelle Arrondel, Martin Helmstädter, Olivia Boyer, Olivier Gribouval, Marie-Claire Gubler, Geraldine Mollet and 15 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. AbioRxiv : the preprint server for biology · 2024
    Article
  7. Model organisms for functional validation in genetic renal disease.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2022
    Article
  8. Review
  9. Review
  10. Review
  11. UsingFrontiers in cell and developmental biology · 2022
    Review
  12. Review
  13. A Mutation inJournal of the American Society of Nephrology : JASN · 2020
    Article
  14. Review
  15. Filling the Gap:Journal of the American Society of Nephrology : JASN · 2019
    Article
  16. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 9 institutions in 3 countries.

Sara GonçalvesLaboratory of Hereditary Kidney Diseases, Institut National de la Santé et de la Recherche Médicale (Inserm) UMR1163, Imagine Institute, Paris, France.
Julie PatatLaboratory of Hereditary Kidney Diseases, Institut National de la Santé et de la Recherche Médicale (Inserm) UMR1163, Imagine Institute, Paris, France.ORCID 0000-0002-6449-2724
Maria Clara GuidaDevelopment, Aging and Regeneration Program, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA, United States of America.
Noelle LachausséeLaboratory of Hereditary Kidney Diseases, Institut National de la Santé et de la Recherche Médicale (Inserm) UMR1163, Imagine Institute, Paris, France.
Christelle ArrondelLaboratory of Hereditary Kidney Diseases, Institut National de la Santé et de la Recherche Médicale (Inserm) UMR1163, Imagine Institute, Paris, France.
Martin HelmstädterDepartment of Medicine IV, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Olivia BoyerLaboratory of Hereditary Kidney Diseases, Institut National de la Santé et de la Recherche Médicale (Inserm) UMR1163, Imagine Institute, Paris, France.ORCID 0000-0002-3957-1359
Olivier GribouvalLaboratory of Hereditary Kidney Diseases, Institut National de la Santé et de la Recherche Médicale (Inserm) UMR1163, Imagine Institute, Paris, France.ORCID 0000-0003-0238-8224
Marie-Claire GublerLaboratory of Hereditary Kidney Diseases, Institut National de la Santé et de la Recherche Médicale (Inserm) UMR1163, Imagine Institute, Paris, France.
Geraldine MolletLaboratory of Hereditary Kidney Diseases, Institut National de la Santé et de la Recherche Médicale (Inserm) UMR1163, Imagine Institute, Paris, France.
Marlène RioDepartment of Genetics, Hôpital Necker-Enfants Malades, AP-HP, Paris, France.
Marina CharbitDepartment of Pediatric Nephrology, Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et de l'Adulte (MARHEA), Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Christine Bole-FeysotUniversité Paris Descartes-Sorbonne Paris Cité, Imagine Institute, Paris, France.
Patrick NitschkeUniversité Paris Descartes-Sorbonne Paris Cité, Imagine Institute, Paris, France.
Tobias B HuberDepartment of Medicine IV, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Patricia G WheelerDivision of Genetics, Arnold Palmer Hospital for Children, Orlando Health, Orlando, FL, United States of America.
Devon HaynesDivision of Genetics, Arnold Palmer Hospital for Children, Orlando Health, Orlando, FL, United States of America.
Jane JuusolaGeneDx, Inc, Gaithersburg, MD, United States of America.
Thierry Billette de VillemeurSorbonne Université, UPMC, GRC ConCer-LD and AP-HP, Hôpital Trousseau, Service de Neuropédiatrie-Pathologie du développement, Paris, France.
Caroline NavaSorbonne Universités, UPMC Univ Paris 06, Inserm U1127, CNRS UMR 7225, Institut du Cerveau et de la Moèlle Épinière (ICM), Paris, France.
Alexandra AfenjarAP-HP, Hôpital Trousseau, Centre de référence des malformations et maladies congénitales du cervelet, Département de génétique et embryologie médicale, Paris, France.
Boris KerenAP-HP, GH Pitié-Salpêtrière, Department of Genetics, Unit of Developmental Genomics, Paris, France.
Rolf BodmerDevelopment, Aging and Regeneration Program, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA, United States of America.ORCID 0000-0001-9087-1210
Corinne AntignacLaboratory of Hereditary Kidney Diseases, Institut National de la Santé et de la Recherche Médicale (Inserm) UMR1163, Imagine Institute, Paris, France.ORCID 0000-0002-9934-4940
Matias SimonsLaboratory of Epithelial Biology and Disease, Institut National de la Santé et de la Recherche Médicale (Inserm) UMR1163, Imagine Institute, Paris, France.ORCID 0000-0003-3959-6350
Délégation Paris 5 · FRHôpital Necker-Enfants Malades · FROrlando Health · USSanford Burnham Prebys Medical Discovery Institute · USSorbonne Université · FRCentre National de la Recherche Scientifique · FRInserm · FRUniversität Hamburg · DEUniversity of Freiburg · DE

Funding

HEART DEVELOPMENT IN DROSOPHILAR01HL054732 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BODMER, ROLF · 1995 to 2024
$11.3M
2009 Insulin-like Growth Factors in Physiology and Disease Gordon Research ConferR13AG033456 · NIA · GORDON RESEARCH CONFERENCES · PI ROTWEIN, PETER S · 2009 to 2013
$43k
NHLBI NIH HHS R01 HL054732NIA NIH HHS R13 AG033456
6 · The paper itself

Abstract

Recent evidence suggests that the presence of more than one pathogenic mutation in a single patient is more common than previously anticipated. One of the challenges hereby is to dissect the contribution of each gene mutation, for which animal models such as Drosophila can provide a valuable aid. Here, we identified three families with mutations in ADD3, encoding for adducin-γ, with intellectual disability, microcephaly, cataracts and skeletal defects. In one of the families with additional cardiomyopathy and steroid-resistant nephrotic syndrome (SRNS), we found a homozygous variant in KAT2B, encoding the lysine acetyltransferase 2B, with impact on KAT2B protein levels in patient fibroblasts, suggesting that this second mutation might contribute to the increased disease spectrum. In order to define the contribution of ADD3 and KAT2B mutations for the patient phenotype, we performed functional experiments in the Drosophila model. We found that both mutations were unable to fully rescue the viability of the respective null mutants of the Drosophila homologs, hts and Gcn5, suggesting that they are indeed pathogenic in flies. While the KAT2B/Gcn5 mutation additionally showed a significantly reduced ability to rescue morphological and functional defects of cardiomyocytes and nephrocytes (podocyte-like cells), this was not the case for the ADD3 mutant rescue. Yet, the simultaneous knockdown of KAT2B and ADD3 synergistically impaired kidney and heart function in flies as well as the adhesion and migration capacity of cultured human podocytes, indicating that mutations in both genes may be required for the full clinical manifestation. Altogether, our studies describe the expansion of the phenotypic spectrum in ADD3 deficiency associated with a homozygous likely pathogenic KAT2B variant and thereby identify KAT2B as a susceptibility gene for kidney and heart disease in ADD3-associated disorders.

Indexed as

MutationAbnormalities, MultipleAdducinsAdolescentAdultAnimalsCalmodulin-Binding ProteinsCell LineCells, CulturedDNA Mutational AnalysisDrosophilaDrosophila ProteinsFemaleHeart DiseasesHomozygoteHumansADD3 protein, humanAdducinsCalmodulin-Binding ProteinsDrosophila ProteinsKAT2B protein, humanp300-CBP-Associated Factorp300-CBP Transcription Factors

Identifiers

PMID29768408
PMCPMC5973622
OpenAlexW2803970043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.